Journal Article Summary
The article investigates the cardiac effects and safety of paroxetine, a selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorder and anxiety disorders. This study is important because some SSRIs have been linked to prolonged QT intervals, which can lead to serious heart issues. However, there has been limited clinical evidence specifically examining paroxetine's effect on the QT interval, making it crucial to understand its safety profile in this regard.
In this study, 38 healthy adults aged 18 to 65, with no history of cardiac disease or mood disorders, participated in an open-label, single-arm, dose-escalating trial. Participants received paroxetine at doses of 20 mg, 40 mg, and 60 mg daily for one week each, while their heart activity was monitored through electrocardiograms (ECGs) and blood samples were taken to measure drug concentration. The results showed that there was no significant change in the corrected QT interval (QTcF) associated with paroxetine, indicating that the drug does not prolong the QT interval in a clinically meaningful way at therapeutic doses.
Despite the positive findings, the study has limitations, including the lack of a placebo group and the focus on healthy volunteers, which may not fully represent patients with existing health conditions. Readers should discuss any concerns about paroxetine and heart health with their healthcare provider, especially if they have a history of cardiovascular issues or are taking other medications that could affect heart rhythm. Overall, the study supports the safety of paroxetine regarding its cardiac effects, but further research may be needed to confirm these findings in broader patient populations.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- van Dijkman Sven C., Félices Mathieu, Pandurangavittal Bhaskar, Ghorpade Sanman, Easterbrook Caroline, Zabielski Marcin, Della Pasqua Oscar. An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults. British Journal of Clinical Pharmacology 2026. DOI: 10.1002/bcp.70398. PMID: 41535245. PMCID: PMC13122290.
Featured Pill Pals Product
Paroxetine 10 mg Tablets --- 30 Count --- Generic for Paxil --- Zydus Pharma
Paroxetine 10 mg Tablets — 30 Count — Generic for Paxil — Zydus Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
